Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0000899243-19-024777

Chief R&D Officer acquired 75,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2019-10-01 Grant or award +75,000 295,657 D
Derivatives
Zalevsky Jonathan Chief R&D Officer 2019-10-01 Grant or award · Stock Option +150,000 150,000 D
Loading xslF345X03/doc4.xml…